Compare ZYME & CHCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ZYME | CHCO |
|---|---|---|
| Founded | 2003 | 1957 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 2022 | 1995 |
| Metric | ZYME | CHCO |
|---|---|---|
| Price | $22.49 | $128.13 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 11 | 2 |
| Target Price | $38.90 | ★ $132.50 |
| AVG Volume (30 Days) | ★ 608.4K | 74.1K |
| Earning Date | 05-07-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 2.87% |
| EPS Growth | ★ 33.33 | 13.18 |
| EPS | N/A | ★ 2.20 |
| Revenue | ★ $105,965,000.00 | N/A |
| Revenue This Year | $183.10 | $5.16 |
| Revenue Next Year | N/A | $3.12 |
| P/E Ratio | ★ N/A | $58.17 |
| Revenue Growth | ★ 38.87 | N/A |
| 52 Week Low | $11.86 | $113.21 |
| 52 Week High | $29.75 | $133.59 |
| Indicator | ZYME | CHCO |
|---|---|---|
| Relative Strength Index (RSI) | 34.96 | 56.90 |
| Support Level | $22.28 | $120.54 |
| Resistance Level | $23.66 | $128.79 |
| Average True Range (ATR) | 0.89 | 2.48 |
| MACD | -0.14 | 0.32 |
| Stochastic Oscillator | 8.05 | 59.67 |
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
City Holding Co is a financial holding company. The company conducts its principal activities through its wholly-owned subsidiary, City National Bank of West Virginia (City National). Through the bank, it provides banking, trust and investment management, and other financial solutions through its network of banking offices located in the states of West Virginia, Virginia, southeastern Ohio, and Kentucky. It offers various products and services such as overdraft facilities, savings accounts, credit cards and debit cards, loans for various purposes, investment advisory, securities brokerage, insurance products, and others. The company's business activities are currently limited to one reportable business segment, which is community banking.